Literature DB >> 3572745

In vitro protein binding of diclofenac sodium in plasma and synovial fluid.

K K Chan, K H Vyas, K D Brandt.   

Abstract

The in vitro protein binding behavior of diclofenac sodium (sodium[o-(2,6-dichloroanilino)phenyl]acetate) in plasma and synovial fluid was investigated by equilibrium dialysis. The drug was highly protein bound (approximately 99.5%) and the extent of binding remained constant for drug concentrations of 2-10 micrograms/mL. Comparable results were obtained with human serum albumin solution (45 g/L) indicating that albumin is probably the responsible protein. The extent of binding remained relatively constant for drug concentrations of 0.25-10 micrograms/mL when albumin concentrations were greater than 25 g/L. For albumin concentrations less than 10 g/L, the extent of binding tended to decrease with increased drug concentration. This concentration (10 g/L) is substantially lower than that usually observed in plasma or synovial fluid of arthritic patients. Curvature of the Scatchard plot indicated the existence of two classes of sites. Excellent results were obtained from fitting of the data according to two classes of sites (r2 greater than 0.999). Parameter estimates (SEM) of the number of binding sites, n1 and n2, and the corresponding association constants, k1 and k2, were 2.26 (0.55), 10.20 (0.69), and 1.32 (0.54) X 10(5) M-1, and 3.71 (1.11) X 10(3) M-1, respectively. Simultaneous samples obtained from arthritic patients indicate considerably higher total protein and albumin concentrations in plasma compared with synovial fluid, but the albumin:total protein ratios were essentially the same. There was very little difference in plasma binding in arthritic patients compared with normal subjects. The extent of binding in synovial fluid samples was consistently lower than that for plasma samples (mean +/- SD of 99.5 +/- 0.2% versus 99.7 +/- 0.1%, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3572745     DOI: 10.1002/jps.2600760204

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  15 in total

Review 1.  Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid.

Authors:  R O Day; A J McLachlan; G G Graham; K M Williams
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 2.  Recent findings on the pharmacokinetics of non-steroidal anti-inflammatory drugs in synovial fluid.

Authors:  P Netter; B Bannwarth; M J Royer-Morrot
Journal:  Clin Pharmacokinet       Date:  1989-09       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls.

Authors:  N M Davies; K E Anderson
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

4.  Serum protein binding of nonsteroidal antiinflammatory drugs: a comparative study.

Authors:  O Borgå; B Borgå
Journal:  J Pharmacokinet Biopharm       Date:  1997-02

5.  Plasma and synovial fluid meclofenamic acid concentrations in patients with rheumatoid arthritis of the knee.

Authors:  J R Koup; D Thomas; E Tucker; A Black; M Ruderman; J A Dixon; A Kinkel
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  An Inexpensive, In-House-Made, Microdialysis Device for Measuring Drug-Protein Binding.

Authors:  Zackary M Herbst; Sayaka Shibata; Erkang Fan; Michael H Gelb
Journal:  ACS Med Chem Lett       Date:  2017-09-28       Impact factor: 4.345

7.  Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans.

Authors:  D J Carlile; N Hakooz; M K Bayliss; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

8.  Prediction and evaluation of fetal toxicity induced by NSAIDs using transplacental kinetic parameters obtained from human placental perfusion studies.

Authors:  Kyohei Shintaku; Satoko Hori; Hiroki Satoh; Kiyomi Tsukimori; Hitoo Nakano; Tomoyuki Fujii; Yuji Taketani; Hisakazu Ohtani; Yasufumi Sawada
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

9.  Diclofenac concentrations in synovial fluid and plasma after cutaneous application in inflammatory and degenerative joint disease.

Authors:  J Radermacher; D Jentsch; M A Scholl; T Lustinetz; J C Frölich
Journal:  Br J Clin Pharmacol       Date:  1991-05       Impact factor: 4.335

10.  Suppression of gastric acid increases the risk of developing immunoglobulin E-mediated drug hypersensitivity: human diclofenac sensitization and a murine sensitization model.

Authors:  A B Riemer; S Gruber; I Pali-Schöll; T Kinaciyan; E Untersmayr; E Jensen-Jarolim
Journal:  Clin Exp Allergy       Date:  2009-10-07       Impact factor: 5.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.